Frontlight ResearchEarly access
TerminatedPhase 3
Cannabidiol and Management of Endometriosis Pain
Key facts
- Who runs it
- Milton S. Hershey Medical Center
- Where
- Hershey, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 3
- People taking part
- 12 people enrolled
- Started
- 4 Dec 2020
- Ended
- 26 Jun 2024
- Type of study
- Interventional, 3 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Cannabidiol (CBD) Extract
- Norethindrone Acetate
- Placebo
- Record updated
- 4 April 2025
- Why it stopped
- Recruitment has been challenging due to the BMI cutoff, need to take oral progesterone and abstain from cannabis products prior to the study.
Who can take part
- Age
- 18 years to 45 years
- Sex
- Women only
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Females ages 18-45 years at the time of enrollment
- A surgical diagnosis with direct visualization and/or histopathologic confirmation of endometriosis with associated moderate to severe endometriosis related pain ( > 3 on a VAS)
- Is not expected to undergo gynecological surgery or other surgical procedure for treatment of endometriosis during the study period
- Agrees to use approved contraception during the entire study if not surgically sterile
- Patients using oral contraceptives, vaginal ring, injectable progesterone and/or GnRH agonists/antagonist for contraception and/or management of endometriosis, can be included if both they and their primary provider agree to stopping their medication and transitioning to Norethindrone acetate (NETA) as the primary treatment of endometriosis throughout the study period
- Patients using Long-acting reversible contraceptives (LARCs) for contraception and/or management of endometriosis can be included if both they and their primary provider agree to initiate Norethindrone (NETA) as the primary treatment of endometriosis throughout the study period
Who cannot take part
- Women with chronic daily opioid use and any chronic pain or frequently reoccurring pain condition, other than endometriosis, that is treated with opioids for > 14 days per month
- Women that are currently using Cannabis based products or have used them within 30 days of enrollment
- Women with chronic use of drugs (defined as > 10 days/month) that cause somnolence/sedation such as benzodiazepines or Central Nervous System (CNS) depressants that are unwilling or unable to discontinue the medications for the washout period and the duration of the study
- Women who are currently taking Clobazam or Valproate and are unwilling/unable to discontinue the medication for the washout period and the duration of the study
- Current use of a progestin-containing contraceptive implant
- Known history of or suspected breast cancer on screening physical exam
- History of or active deep venous thrombosis or pulmonary embolism
- History of or active arterial thromboembolic event (e.g. stroke, myocardial infarction)
- Multiple (> 3) risk factors for arterial vascular disease (e.g. uncontrolled hypertension, diabetes mellitus, hypercholesterolemia, obesity and smoking)
- Women with known liver disease, such as hepatitis, or with screening LFTS (AST/ALT) > 3 times above the upper limits of normal (ULN) in the past year
- Women that are pregnant, breastfeeding or trying to conceive
- Non-English speaking or inability to read and understand English
- Women with a BMI > 35 kg/m2
- Women with chronic alcohol use (defined as > 3 drinks per day, averaged over one week)
- Women with suicidal ideation or uncontrolled depression within the past year
Where in United States
- Penn State Health Milton S. Hershey Medical CenterHershey, United States
About the trial
What the trial wants to find out
The investigators are looking to conduct a study looking at the effects of cannabidiol (CBD) in patients with endometriosis. It is believed that CBD will improve both pain and quality of life. The study will last a total of 12 weeks and involve several onsite visits in addition to daily pain assessments.
The 3 groups in the trial
- Group A - PlaceboPlacebo, for comparison
Norethindrone acetate (5mg daily) + Placebo
Treatment: Norethindrone Acetate and Placebo
- Group B - Low Dose CBDExisting treatment, for comparison
Norethindrone acetate (5mg daily) + Low dose CBD (10mg sublingual daily)
Treatment: Cannabidiol (CBD) Extract and Norethindrone Acetate
- Group C - High Dose CBDExisting treatment, for comparison
Norethindrone acetate (5mg daily) + High dose CBD (20mg sublingual daily)
Treatment: Cannabidiol (CBD) Extract and Norethindrone Acetate
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Randomized Controlled Pilot Study of the Use of Cannabidiol in the Management of Endometriosis Pain
- Record updated
- 4 April 2025